Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC
- PMID: 18695931
- DOI: 10.1007/s00213-008-1260-2
Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC
Abstract
Rationale: Delta9-Tetrahydrocannabinol (THC) is the main active constituent of cannabis. In recent years, the average THC content of some cannabis cigarettes has increased up to approximately 60 mg per cigarette (20% THC cigarettes). The pharmacokinetics of THC after smoking cannabis cigarettes containing more than approximately 35 mg THC (3.55% THC cigarettes) is unknown. To be able to perform suitable exposure risk analysis, it is important to know if there is a linear relation at higher doses.
Objectives: The present study aimed to characterise the pharmacokinetics of THC, the active metabolite 11-OH-THC and the inactive metabolite THC-COOH after smoking a combination of tobacco and cannabis containing high THC doses.
Materials and methods: This double-blind, placebo-controlled, four-way, cross-over study included 24 male non-daily cannabis users (two to nine joints per month). Participants were randomly assigned to smoke cannabis cigarettes containing 29.3, 49.1 and 69.4 mg THC and a placebo. Serial serum samples collected over a period of 0-8 h were analysed by liquid chromatography electrospray tandem mass spectrometry. Effects on heart rate, blood pressure and 'high' feeling were also measured.
Results: Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively. A large inter-individual variability in Cmax was observed. Heart rate and 'high' feeling significantly increased with increasing THC dose.
Conclusions: This study demonstrates that the known linear association between THC dose and THC serum concentration also applies for high THC doses.
Similar articles
-
Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).Psychopharmacology (Berl). 2009 May;204(1):85-94. doi: 10.1007/s00213-008-1440-0. Epub 2008 Dec 20. Psychopharmacology (Berl). 2009. PMID: 19099294 Clinical Trial.
-
Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.Psychopharmacology (Berl). 2014 Dec;231(24):4723-33. doi: 10.1007/s00213-014-3630-2. Epub 2014 May 31. Psychopharmacology (Berl). 2014. PMID: 24879495 Clinical Trial.
-
Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model.Toxicol Appl Pharmacol. 2010 Aug 1;246(3):148-53. doi: 10.1016/j.taap.2010.04.019. Epub 2010 May 4. Toxicol Appl Pharmacol. 2010. PMID: 20450927 Clinical Trial.
-
[Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis].Bull Acad Natl Med. 2014 Mar;198(3):541-56; discussion 556-7. Bull Acad Natl Med. 2014. PMID: 26427296 Review. French.
-
Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis.Neurosci Biobehav Rev. 2022 Mar;134:104433. doi: 10.1016/j.neubiorev.2021.11.004. Epub 2021 Nov 9. Neurosci Biobehav Rev. 2022. PMID: 34767878 Review.
Cited by
-
CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1).Biochem Pharmacol. 2024 Oct;228:116191. doi: 10.1016/j.bcp.2024.116191. Epub 2024 Apr 5. Biochem Pharmacol. 2024. PMID: 38583809 Free PMC article.
-
Smokeless consumption of medical cannabis pharmacokinetics, safety and feasibility of the CannaHALER© a phase 1a study.J Cannabis Res. 2020 Mar 26;2(1):15. doi: 10.1186/s42238-020-00022-4. J Cannabis Res. 2020. PMID: 33526119 Free PMC article.
-
An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.Pharmaceutics. 2025 Mar 1;17(3):319. doi: 10.3390/pharmaceutics17030319. Pharmaceutics. 2025. PMID: 40142983 Free PMC article. Review.
-
Acute effects of oral delta-9-tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects.Psychophysiology. 2022 Feb;59(2):e13955. doi: 10.1111/psyp.13955. Epub 2021 Oct 19. Psychophysiology. 2022. PMID: 34665890 Free PMC article.
-
Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.J Psychopharmacol. 2019 Sep;33(9):1160-1169. doi: 10.1177/0269881119862533. Epub 2019 Aug 13. J Psychopharmacol. 2019. PMID: 31407943 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical